Fair Value Measurements - Milestone Asset, Milestone Contingent Consideration and PRV Interest and Warrants (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
Feb. 24, 2025 |
Feb. 28, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Fair Value Measurements | ||||
| Exarafenib milestone asset (Note 6) | $ 3,704 | $ 3,600 | ||
| Exarafenib milestone contingent consideration | 3,704 | 3,600 | ||
| Fair value of warrants | 709 | 697 | ||
| Fair value of the share-based liability | 3,197 | |||
| Level 3 | ||||
| Fair Value Measurements | ||||
| Fair value of the share-based liability | 0 | 3,200 | ||
| Kinnate CVR holders | CVR Agreement | ||||
| Fair Value Measurements | ||||
| Exarafenib milestone asset (Note 6) | 3,700 | |||
| Exarafenib milestone contingent consideration | 3,700 | $ 3,600 | ||
| Increase in Exarafenib milestone asset | 100 | |||
| Increase in Exarafenib milestone contingent consideration | 100 | |||
| Castle Creek Biosciences, Inc | Royalty Financing Transaction | ||||
| Fair Value Measurements | ||||
| Rights entity acquired as a percentage of specified percentage | 6.70% | 6.70% | ||
| Fair value of warrants | $ 700 |
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value during the period from contingent consideration liability. No definition available.
|
| X | ||||||||||
- Definition Fair value of investment in warrants, classified as noncurrent. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825. No definition available.
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. No definition available.
|
| X | ||||||||||
- Definition The rights entity acquired as a percentage of specified percentage of net sales or as a specified percentage of proceeds from potential Priority Review Voucher. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|